Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD5 | P21918 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 4/20 | 0.32 |
| ▸ | STAT3 | P40763 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | SCN1A | P35498 | 1/20 | 0.30 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.30 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4303080 | 0.80 | HTR7 (0.36) | KAT2BCHRNB2CHRNA4CYP1A2CYP2D6 | |
| SCHEMBL6892797 | 0.77 | DRD2 (0.58) | KAT2BDRD2DRD1DRD4DRD5 | |
| SCHEMBL7755878 | 0.74 | LTA4H (0.56) | CHRNB2CHRNA4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6651166 | 0.73 | KDM4E (0.38) | KAT2BCHRNB2CHRNA4DRD2DRD1 | |
| SCHEMBL6650105 | 0.73 | NR4A2 (0.42) | CHRNB2CHRNA4CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL6651356 | 0.73 | DRD2 (0.44) | KAT2BCHRNB2CHRNA4DRD2DRD1 | |
| Citric Acid SCHEMBL4902056 | 0.69 | KDM4E (0.49) | CYP1A2CYP2D6CYP2C9CYP2C19 | |
| Citric Acid SCHEMBL8657218 | 0.66 | KDM4E (0.70) | CYP1A2CYP2D6CYP2C9CYP2C19DRD2 | |
| SCHEMBL20706621 | 0.64 | ADRA1D (0.43) | KAT2B | |
| SCHEMBL20706617 | 0.63 | TDP1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200693-A1 | Derivatives of Aryl (or Heteroaryl) Azolylcarbinols (in Particular Cizolirtin Citrate) for the Treatment of Opioid Addiction | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2008-08-21 | — | — | US | claimed |
| US-20070088024-A1 | Active substance combination comprising a carbinol combined to at least an NSAID | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-04-19 | — | — | US | claimed |
| US-20070082893-A1 | Active substance combination | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2007-04-12 | — | — | US | claimed |
| WO-2005097192-A9 | ACTIVE SUBSTANCE COMBINATION OF A CARBINOL COMPOUND AND AN OPIOID | ESTEVE LABOR DR (ES) | 2007-01-18 | — | — | WO | claimed |
| EP-1695704-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-08-30 | — | — | EP | claimed |
| EP-1690537-A1 | Derivatives of aryl(or heteroaryl) azolycarbinols for the treatment of fibromyalgia | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-08-16 | — | — | EP | claimed |
| EP-1642577-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of central neuropathic pain | Laboratorios del Dr. Esteve S.A. (ES) | 2006-04-05 | — | — | EP | claimed |
| EP-1632227-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinols (in particular cizolirtin citrate) for the treatment of opioid addiction | Laboratorios del Dr. Esteve S.A. (ES) | 2006-03-08 | — | — | EP | claimed |
| US-20060040924-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of renal colic | LABORATORIOS DR. ESTEVE S.A. (ES) | 2006-02-23 | — | — | US | claimed |
| EP-1584335-A2 | Active substance combination comprising a carbinol composition and an opioid | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-10-12 | — | — | EP | claimed |
| US-20050222135-A1 | Active substance combination | LABORATIONS DEL DR. ESTEVE S.A. (ES) | 2005-10-06 | — | — | US | claimed |
| EP-1072266-B1 | THIENYLAZOLYLALCOXYETHANAMINES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2005-08-24 | — | — | EP | claimed |
| US-20040162324-A1 | Thienylazolylalkoxyethanamines, their preparation and their application as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. | 2004-08-19 | — | — | US | claimed |
| EP-1103243-B1 | UTILIZATION OF ARYL(OR HETEROARYL)AZOLYLCARBINOL DERIVATIVES FOR THE TREATMENT OF TROUBLES MEDIATED BY AN EXCESS OF SUBSTANCE P | ESTEVE LABOR DR (ES) | 2004-01-07 | — | — | EP | claimed |
| US-6518295-B1 | Such as anxiety, depression, schizophrenia, manic depressive psychosis, sexual dysfunction, drug addiction, cognitive disorders, and locomotive disorders | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2003-02-11 | — | — | US | claimed |
| US-20020188017-A1 | Thienylazolylalkoxyethanamines, their preparation and their application as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. | 2002-12-12 | — | — | US | claimed |
| US-6410582-B1 | ANALGESICS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2002-06-25 | — | — | US | claimed |
| EP-1103243-A2 | UTILIZATION OF ARYL(OR HETEROARYL)AZOLYLCARBINOL DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF TROUBLES MEDIATED BY AN EXCESS OF SUBSTANCE P | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2001-05-30 | — | — | EP | claimed |
| EP-1072266-A1 | THIENYLAZOLYLALCOXYETHANAMINES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2001-01-31 | — | — | EP | claimed |
| US-20080200693-A1 | Derivatives of Aryl (or Heteroaryl) Azolylcarbinols (in Particular Cizolirtin Citrate) for the Treatment of Opioid Addiction | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2008-08-21 | — | — | US | disclosed |
| US-20070088024-A1 | Active substance combination comprising a carbinol combined to at least an NSAID | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-04-19 | — | — | US | disclosed |
| US-20070082893-A1 | Active substance combination | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2007-04-12 | — | — | US | disclosed |
| EP-1755678-A2 | ACTIVE SUBSTANCE COMBINATION OF A CARBINOL COMPOUND AND AN OPIOID | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-02-28 | — | — | EP | disclosed |
| EP-1746986-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A CARBINOL COMBINED TO AT LEAST AN NSAID | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005097192-A9 | ACTIVE SUBSTANCE COMBINATION OF A CARBINOL COMPOUND AND AN OPIOID | ESTEVE LABOR DR (ES) | 2007-01-18 | — | — | WO | disclosed |
| US-7129361-B2 | Thienylazolylalkoxyethanamines, their preparation and their application as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-10-31 | — | — | US | disclosed |
| EP-1695704-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-08-30 | — | — | EP | disclosed |
| EP-1690537-A1 | Derivatives of aryl(or heteroaryl) azolycarbinols for the treatment of fibromyalgia | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-08-16 | — | — | EP | disclosed |
| EP-1642577-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of central neuropathic pain | Laboratorios del Dr. Esteve S.A. (ES) | 2006-04-05 | — | — | EP | disclosed |
| EP-1632227-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinols (in particular cizolirtin citrate) for the treatment of opioid addiction | Laboratorios del Dr. Esteve S.A. (ES) | 2006-03-08 | — | — | EP | disclosed |
| US-20060040924-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of renal colic | LABORATORIOS DR. ESTEVE S.A. (ES) | 2006-02-23 | — | — | US | disclosed |
| WO-2005097192-A2 | ACTIVE SUBSTANCE COMBINATION OF A CARBINOL COMPOUND AND AN OPIOID | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005097099-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A CARBINOL COMBINED TO AT LEAST AN NSAID | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-10-20 | — | — | WO | disclosed |
| EP-1584335-A2 | Active substance combination comprising a carbinol composition and an opioid | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-10-12 | — | — | EP | disclosed |
| US-20050222136-A1 | Active substance combination | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-10-06 | — | — | US | disclosed |
| US-20050222135-A1 | Active substance combination | LABORATIONS DEL DR. ESTEVE S.A. (ES) | 2005-10-06 | — | — | US | disclosed |
| US-20040162324-A1 | Thienylazolylalkoxyethanamines, their preparation and their application as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. | 2004-08-19 | — | — | US | disclosed |
| US-20020188017-A1 | Thienylazolylalkoxyethanamines, their preparation and their application as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. | 2002-12-12 | — | — | US | disclosed |
| US-6410582-B1 | ANALGESICS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2002-06-25 | — | — | US | disclosed |
| US-6410582-B1 | ANALGESICS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2002-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222135-A1 | Active substance combination | OPRM1, OPRK1, OPRL1 | KAT2B 2557/4885CHRNB2 1765/4885CHRNA4 1367/4885 |
| US-20020188017-A1 | Thienylazolylalkoxyethanamines, their preparation and their application as medicaments | HNMT, HRH4, PNMT | KAT2B 3553/4885CHRNB2 1255/4885CHRNA4 324/4885 |
| US-20040162324-A1 | Thienylazolylalkoxyethanamines, their preparation and their application as medicaments | HNMT, HRH4, PNMT | KAT2B 3553/4885CHRNB2 1255/4885CHRNA4 324/4885 |
| US-20070088024-A1 | Active substance combination comprising a carbinol combined to at least an NSAID | PTGS1, PTGS2, PTGES2 | KAT2B 3332/4885CHRNB2 4298/4885CHRNA4 4203/4885 |
| US-20080200693-A1 | Derivatives of Aryl (or Heteroaryl) Azolylcarbinols (in Particular Cizolirtin Citrate) for the Treatment of Opioid Addiction | CNR2, CNR1, HCRTR2 | KAT2B 500/4885CHRNB2 188/4885CHRNA4 284/4885 |
| US-20050222136-A1 | Active substance combination | PTGS1, MMP8, TACR1 | KAT2B 2987/4885CHRNB2 3667/4885CHRNA4 3650/4885 |
| US-20060040924-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of renal colic | SLC10A2, FABP2, FANCI | KAT2B 2869/4885CHRNB2 4219/4885CHRNA4 4793/4885 |
| US-20070082893-A1 | Active substance combination | OPRM1, OPRK1, OPRL1 | KAT2B 2557/4885CHRNB2 1765/4885CHRNA4 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.